Supplementary Materials Supplementary Table 1. Methods Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co\primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20)… Continue reading Supplementary Materials Supplementary Table 1. Methods Patients were randomly allocated to